The Impact of Extended Treatment with AL on Antimalarial Exposure and Reinfection Risks in Ugandan Children with Uncomplicated Malaria

Clin Infect Dis

Extending the duration of artemether-lumefantrine (AL) was safe and significantly enhanced overall drug exposure in young children but did not lead to significant reductions in recurrent parasitemia risk in our high transmission setting. However, day 7 levels were strongly predictive of recurrent parasitemia risk and those in the lowest weight-band were at higher risk of underdosing with the standard 3-day regimen.